nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—SLC6A2—Clonidine—glaucoma	0.0945	0.147	CbGbCtD
Levomilnacipran—CYP2D6—Carteolol—glaucoma	0.0765	0.119	CbGbCtD
Levomilnacipran—CYP2D6—Betaxolol—glaucoma	0.0517	0.0807	CbGbCtD
Levomilnacipran—CYP2C19—Methazolamide—glaucoma	0.0515	0.0804	CbGbCtD
Levomilnacipran—CYP2C19—Timolol—glaucoma	0.0438	0.0684	CbGbCtD
Levomilnacipran—CYP2D6—Methazolamide—glaucoma	0.0392	0.0611	CbGbCtD
Levomilnacipran—CYP3A4—Pilocarpine—glaucoma	0.0369	0.0575	CbGbCtD
Levomilnacipran—ABCB1—Timolol—glaucoma	0.0354	0.0552	CbGbCtD
Levomilnacipran—CYP2D6—Timolol—glaucoma	0.0333	0.052	CbGbCtD
Levomilnacipran—ABCB1—Clonidine—glaucoma	0.0301	0.0469	CbGbCtD
Levomilnacipran—CYP3A4—Brinzolamide—glaucoma	0.0289	0.0452	CbGbCtD
Levomilnacipran—CYP2D6—Clonidine—glaucoma	0.0283	0.0442	CbGbCtD
Levomilnacipran—CYP3A4—Dorzolamide—glaucoma	0.0279	0.0436	CbGbCtD
Levomilnacipran—CYP3A4—Methazolamide—glaucoma	0.0249	0.0389	CbGbCtD
Levomilnacipran—CYP3A4—Acetazolamide—glaucoma	0.0199	0.0311	CbGbCtD
Levomilnacipran—CYP3A4—Clonidine—glaucoma	0.018	0.0281	CbGbCtD
Levomilnacipran—CYP2J2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.00386	0.0836	CbGpPWpGaD
Levomilnacipran—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—glaucoma	0.00188	0.0408	CbGpPWpGaD
Levomilnacipran—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—glaucoma	0.00138	0.0298	CbGpPWpGaD
Levomilnacipran—SLC6A2—Amine compound SLC transporters—SLC6A13—glaucoma	0.00131	0.0283	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—ATOH7—glaucoma	0.00114	0.0247	CbGpPWpGaD
Levomilnacipran—ABCB1—ABC-family proteins mediated transport—PEX19—glaucoma	0.0011	0.0239	CbGpPWpGaD
Levomilnacipran—SLC6A4—Monoamine Transport—SLC6A1—glaucoma	0.00106	0.0229	CbGpPWpGaD
Levomilnacipran—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.000964	0.0209	CbGpPWpGaD
Levomilnacipran—SLC6A2—Amine compound SLC transporters—SLC6A1—glaucoma	0.000956	0.0207	CbGpPWpGaD
Levomilnacipran—CYP2J2—Tryptophan metabolism—CYP1B1—glaucoma	0.000953	0.0206	CbGpPWpGaD
Levomilnacipran—SLC6A2—Monoamine Transport—SLC6A1—glaucoma	0.000908	0.0197	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.000901	0.0195	CbGpPWpGaD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000892	0.0193	CbGpPWpGaD
Levomilnacipran—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.000878	0.019	CbGpPWpGaD
Levomilnacipran—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.000861	0.0186	CbGpPWpGaD
Levomilnacipran—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.000783	0.017	CbGpPWpGaD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000771	0.0167	CbGpPWpGaD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000761	0.0165	CbGpPWpGaD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000625	0.0135	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—glaucoma	0.000511	0.0111	CbGpPWpGaD
Levomilnacipran—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—glaucoma	0.000471	0.0102	CbGpPWpGaD
Levomilnacipran—CYP3A4—Aflatoxin B1 metabolism—GSTM1—glaucoma	0.00046	0.00997	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—OPN4—glaucoma	0.000455	0.00984	CbGpPWpGaD
Levomilnacipran—CYP2C8—Tamoxifen metabolism—CYP1B1—glaucoma	0.000446	0.00965	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—SLC6A13—glaucoma	0.000428	0.00927	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—GSTT1—glaucoma	0.000417	0.00902	CbGpPWpGaD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—PTGS2—glaucoma	0.000402	0.0087	CbGpPWpGaD
Levomilnacipran—CYP2C19—Tamoxifen metabolism—CYP1B1—glaucoma	0.000398	0.00861	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—glaucoma	0.000374	0.0081	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC6A13—glaucoma	0.000368	0.00798	CbGpPWpGaD
Levomilnacipran—CYP2D6—Tamoxifen metabolism—CYP1B1—glaucoma	0.000366	0.00792	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—TXN—glaucoma	0.000352	0.00762	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000348	0.00753	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—CYP1B1—glaucoma	0.000332	0.00719	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Dorzolamide—glaucoma	0.000329	0.00105	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP1B1—glaucoma	0.000327	0.00709	CbGpPWpGaD
Levomilnacipran—Dyspnoea—Dorzolamide—glaucoma	0.000327	0.00104	CcSEcCtD
Levomilnacipran—Insomnia—Brinzolamide—glaucoma	0.000326	0.00104	CcSEcCtD
Levomilnacipran—Somnolence—Dorzolamide—glaucoma	0.000326	0.00104	CcSEcCtD
Levomilnacipran—Dyspnoea—Travoprost—glaucoma	0.000326	0.00104	CcSEcCtD
Levomilnacipran—Hypotension—Pilocarpine—glaucoma	0.000324	0.00103	CcSEcCtD
Levomilnacipran—Paraesthesia—Brinzolamide—glaucoma	0.000324	0.00103	CcSEcCtD
Levomilnacipran—Dysuria—Timolol—glaucoma	0.000324	0.00103	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.000323	0.007	CbGpPWpGaD
Levomilnacipran—Dyspepsia—Dorzolamide—glaucoma	0.000323	0.00103	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Timolol—glaucoma	0.000322	0.00103	CcSEcCtD
Levomilnacipran—Dyspnoea—Brinzolamide—glaucoma	0.000321	0.00103	CcSEcCtD
Levomilnacipran—Dyspepsia—Travoprost—glaucoma	0.000321	0.00103	CcSEcCtD
Levomilnacipran—Asthenia—Apraclonidine—glaucoma	0.000321	0.00103	CcSEcCtD
Levomilnacipran—Somnolence—Brinzolamide—glaucoma	0.000321	0.00102	CcSEcCtD
Levomilnacipran—Vision blurred—Clonidine—glaucoma	0.00032	0.00102	CcSEcCtD
Levomilnacipran—Decreased appetite—Dorzolamide—glaucoma	0.000319	0.00102	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Timolol—glaucoma	0.000319	0.00102	CcSEcCtD
Levomilnacipran—Urticaria—Acetazolamide—glaucoma	0.000318	0.00102	CcSEcCtD
Levomilnacipran—Tremor—Clonidine—glaucoma	0.000318	0.00102	CcSEcCtD
Levomilnacipran—Dyspepsia—Brinzolamide—glaucoma	0.000317	0.00101	CcSEcCtD
Levomilnacipran—Eye disorder—Betaxolol—glaucoma	0.000317	0.00101	CcSEcCtD
Levomilnacipran—Pruritus—Apraclonidine—glaucoma	0.000316	0.00101	CcSEcCtD
Levomilnacipran—Body temperature increased—Acetazolamide—glaucoma	0.000316	0.00101	CcSEcCtD
Levomilnacipran—Fatigue—Dorzolamide—glaucoma	0.000316	0.00101	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Travoprost—glaucoma	0.000315	0.00101	CcSEcCtD
Levomilnacipran—Fatigue—Travoprost—glaucoma	0.000315	0.00101	CcSEcCtD
Levomilnacipran—Flushing—Betaxolol—glaucoma	0.000315	0.00101	CcSEcCtD
Levomilnacipran—Cardiac disorder—Betaxolol—glaucoma	0.000315	0.00101	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—SLC6A1—glaucoma	0.000314	0.00679	CbGpPWpGaD
Levomilnacipran—Insomnia—Pilocarpine—glaucoma	0.000313	0.001	CcSEcCtD
Levomilnacipran—Decreased appetite—Brinzolamide—glaucoma	0.000313	0.001	CcSEcCtD
Levomilnacipran—Weight decreased—Timolol—glaucoma	0.000313	0.001	CcSEcCtD
Levomilnacipran—Constipation—Travoprost—glaucoma	0.000312	0.000998	CcSEcCtD
Levomilnacipran—Agitation—Clonidine—glaucoma	0.000312	0.000996	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000311	0.000995	CcSEcCtD
Levomilnacipran—Paraesthesia—Pilocarpine—glaucoma	0.000311	0.000994	CcSEcCtD
Levomilnacipran—Asthenia—Bimatoprost—glaucoma	0.000311	0.000994	CcSEcCtD
Levomilnacipran—Fatigue—Brinzolamide—glaucoma	0.000311	0.000993	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.00031	0.00671	CbGpPWpGaD
Levomilnacipran—Dyspnoea—Pilocarpine—glaucoma	0.000309	0.000987	CcSEcCtD
Levomilnacipran—Somnolence—Pilocarpine—glaucoma	0.000308	0.000984	CcSEcCtD
Levomilnacipran—Angiopathy—Betaxolol—glaucoma	0.000308	0.000983	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000307	0.00665	CbGpPWpGaD
Levomilnacipran—Pruritus—Bimatoprost—glaucoma	0.000307	0.00098	CcSEcCtD
Levomilnacipran—Diarrhoea—Apraclonidine—glaucoma	0.000306	0.000978	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Betaxolol—glaucoma	0.000306	0.000977	CcSEcCtD
Levomilnacipran—Dyspepsia—Pilocarpine—glaucoma	0.000305	0.000975	CcSEcCtD
Levomilnacipran—Chills—Betaxolol—glaucoma	0.000304	0.000972	CcSEcCtD
Levomilnacipran—Syncope—Clonidine—glaucoma	0.000304	0.000972	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—TXN—glaucoma	0.000302	0.00655	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Pilocarpine—glaucoma	0.000301	0.000963	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dorzolamide—glaucoma	0.0003	0.000958	CcSEcCtD
Levomilnacipran—Palpitations—Clonidine—glaucoma	0.0003	0.000957	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000299	0.000956	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Travoprost—glaucoma	0.000299	0.000954	CcSEcCtD
Levomilnacipran—Loss of consciousness—Clonidine—glaucoma	0.000298	0.000952	CcSEcCtD
Levomilnacipran—Mental disorder—Betaxolol—glaucoma	0.000297	0.000949	CcSEcCtD
Levomilnacipran—Constipation—Pilocarpine—glaucoma	0.000296	0.000947	CcSEcCtD
Levomilnacipran—Dizziness—Apraclonidine—glaucoma	0.000296	0.000945	CcSEcCtD
Levomilnacipran—Malnutrition—Betaxolol—glaucoma	0.000295	0.000943	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—NARFL—glaucoma	0.000292	0.00632	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CA5A—glaucoma	0.000292	0.00632	CbGpPWpGaD
Levomilnacipran—Urticaria—Dorzolamide—glaucoma	0.000291	0.000931	CcSEcCtD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.00029	0.00629	CbGpPWpGaD
Levomilnacipran—Abdominal pain—Dorzolamide—glaucoma	0.00029	0.000926	CcSEcCtD
Levomilnacipran—Body temperature increased—Dorzolamide—glaucoma	0.00029	0.000926	CcSEcCtD
Levomilnacipran—Tension—Betaxolol—glaucoma	0.00029	0.000926	CcSEcCtD
Levomilnacipran—Dysgeusia—Betaxolol—glaucoma	0.000289	0.000924	CcSEcCtD
Levomilnacipran—Chest pain—Clonidine—glaucoma	0.000289	0.000922	CcSEcCtD
Levomilnacipran—Abdominal pain—Travoprost—glaucoma	0.000289	0.000922	CcSEcCtD
Levomilnacipran—Anxiety—Clonidine—glaucoma	0.000288	0.000919	CcSEcCtD
Levomilnacipran—Asthenia—Acetazolamide—glaucoma	0.000287	0.000917	CcSEcCtD
Levomilnacipran—Dizziness—Bimatoprost—glaucoma	0.000287	0.000916	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000287	0.000916	CcSEcCtD
Levomilnacipran—Urticaria—Brinzolamide—glaucoma	0.000286	0.000915	CcSEcCtD
Levomilnacipran—Vomiting—Apraclonidine—glaucoma	0.000284	0.000909	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Pilocarpine—glaucoma	0.000283	0.000905	CcSEcCtD
Levomilnacipran—Hypersensitivity—Brimonidine—glaucoma	0.000283	0.000904	CcSEcCtD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000283	0.00612	CbGpPWpGaD
Levomilnacipran—Dry mouth—Clonidine—glaucoma	0.000282	0.000902	CcSEcCtD
Levomilnacipran—Dermatitis—Apraclonidine—glaucoma	0.000282	0.0009	CcSEcCtD
Levomilnacipran—Headache—Apraclonidine—glaucoma	0.00028	0.000895	CcSEcCtD
Levomilnacipran—Vision blurred—Betaxolol—glaucoma	0.000278	0.000889	CcSEcCtD
Levomilnacipran—Tremor—Betaxolol—glaucoma	0.000277	0.000884	CcSEcCtD
Levomilnacipran—Hallucination—Timolol—glaucoma	0.000276	0.000881	CcSEcCtD
Levomilnacipran—Asthenia—Brimonidine—glaucoma	0.000276	0.00088	CcSEcCtD
Levomilnacipran—Infection—Clonidine—glaucoma	0.000275	0.000878	CcSEcCtD
Levomilnacipran—Abdominal pain—Pilocarpine—glaucoma	0.000274	0.000875	CcSEcCtD
Levomilnacipran—Body temperature increased—Pilocarpine—glaucoma	0.000274	0.000875	CcSEcCtD
Levomilnacipran—Diarrhoea—Acetazolamide—glaucoma	0.000274	0.000875	CcSEcCtD
Levomilnacipran—Rash—Bimatoprost—glaucoma	0.000273	0.000874	CcSEcCtD
Levomilnacipran—Dermatitis—Bimatoprost—glaucoma	0.000273	0.000873	CcSEcCtD
Levomilnacipran—Oedema peripheral—Timolol—glaucoma	0.000273	0.000872	CcSEcCtD
Levomilnacipran—Shock—Clonidine—glaucoma	0.000272	0.00087	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Timolol—glaucoma	0.000272	0.00087	CcSEcCtD
Levomilnacipran—Pruritus—Brimonidine—glaucoma	0.000272	0.000868	CcSEcCtD
Levomilnacipran—Headache—Bimatoprost—glaucoma	0.000272	0.000868	CcSEcCtD
Levomilnacipran—Nervous system disorder—Clonidine—glaucoma	0.000271	0.000867	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Clonidine—glaucoma	0.000271	0.000866	CcSEcCtD
Levomilnacipran—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.000271	0.00586	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Dorzolamide—glaucoma	0.00027	0.000863	CcSEcCtD
Levomilnacipran—Tachycardia—Clonidine—glaucoma	0.00027	0.000863	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC6A1—glaucoma	0.00027	0.00584	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Travoprost—glaucoma	0.000269	0.00086	CcSEcCtD
Levomilnacipran—Skin disorder—Clonidine—glaucoma	0.000269	0.000859	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Clonidine—glaucoma	0.000268	0.000855	CcSEcCtD
Levomilnacipran—Nausea—Apraclonidine—glaucoma	0.000266	0.000849	CcSEcCtD
Levomilnacipran—Hypersensitivity—Brinzolamide—glaucoma	0.000266	0.000849	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—GSTM1—glaucoma	0.000265	0.00574	CbGpPWpGaD
Levomilnacipran—Syncope—Betaxolol—glaucoma	0.000265	0.000846	CcSEcCtD
Levomilnacipran—Dizziness—Acetazolamide—glaucoma	0.000265	0.000845	CcSEcCtD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000264	0.00572	CbGpPWpGaD
Levomilnacipran—Anorexia—Clonidine—glaucoma	0.000264	0.000843	CcSEcCtD
Levomilnacipran—Asthenia—Dorzolamide—glaucoma	0.000263	0.000841	CcSEcCtD
Levomilnacipran—Asthenia—Travoprost—glaucoma	0.000262	0.000837	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—PEX19—glaucoma	0.000262	0.00567	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—GSTM1—glaucoma	0.000262	0.00567	CbGpPWpGaD
Levomilnacipran—Palpitations—Betaxolol—glaucoma	0.000261	0.000834	CcSEcCtD
Levomilnacipran—Pruritus—Dorzolamide—glaucoma	0.000259	0.000829	CcSEcCtD
Levomilnacipran—Loss of consciousness—Betaxolol—glaucoma	0.000259	0.000829	CcSEcCtD
Levomilnacipran—Eye disorder—Timolol—glaucoma	0.000259	0.000827	CcSEcCtD
Levomilnacipran—Asthenia—Brinzolamide—glaucoma	0.000259	0.000827	CcSEcCtD
Levomilnacipran—Hypotension—Clonidine—glaucoma	0.000259	0.000826	CcSEcCtD
Levomilnacipran—Pruritus—Travoprost—glaucoma	0.000258	0.000825	CcSEcCtD
Levomilnacipran—Nausea—Bimatoprost—glaucoma	0.000258	0.000823	CcSEcCtD
Levomilnacipran—Cardiac disorder—Timolol—glaucoma	0.000257	0.000822	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFB2—glaucoma	0.000256	0.00553	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Pilocarpine—glaucoma	0.000255	0.000816	CcSEcCtD
Levomilnacipran—Pruritus—Brinzolamide—glaucoma	0.000255	0.000815	CcSEcCtD
Levomilnacipran—Vomiting—Acetazolamide—glaucoma	0.000254	0.000813	CcSEcCtD
Levomilnacipran—Dizziness—Brimonidine—glaucoma	0.000254	0.000811	CcSEcCtD
Levomilnacipran—Angiopathy—Timolol—glaucoma	0.000251	0.000803	CcSEcCtD
Levomilnacipran—Chest pain—Betaxolol—glaucoma	0.000251	0.000803	CcSEcCtD
Levomilnacipran—Diarrhoea—Dorzolamide—glaucoma	0.000251	0.000802	CcSEcCtD
Levomilnacipran—Headache—Acetazolamide—glaucoma	0.000251	0.000801	CcSEcCtD
Levomilnacipran—Anxiety—Betaxolol—glaucoma	0.00025	0.0008	CcSEcCtD
Levomilnacipran—Insomnia—Clonidine—glaucoma	0.00025	0.0008	CcSEcCtD
Levomilnacipran—Diarrhoea—Travoprost—glaucoma	0.00025	0.000798	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Timolol—glaucoma	0.00025	0.000798	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.00025	0.000797	CcSEcCtD
Levomilnacipran—Asthenia—Pilocarpine—glaucoma	0.000249	0.000794	CcSEcCtD
Levomilnacipran—Paraesthesia—Clonidine—glaucoma	0.000248	0.000794	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—EDN1—glaucoma	0.000248	0.00538	CbGpPWpGaD
Levomilnacipran—Dyspnoea—Clonidine—glaucoma	0.000247	0.000788	CcSEcCtD
Levomilnacipran—Diarrhoea—Brinzolamide—glaucoma	0.000247	0.000788	CcSEcCtD
Levomilnacipran—Somnolence—Clonidine—glaucoma	0.000246	0.000786	CcSEcCtD
Levomilnacipran—Dry mouth—Betaxolol—glaucoma	0.000246	0.000785	CcSEcCtD
Levomilnacipran—Pruritus—Pilocarpine—glaucoma	0.000245	0.000783	CcSEcCtD
Levomilnacipran—Mental disorder—Timolol—glaucoma	0.000243	0.000775	CcSEcCtD
Levomilnacipran—Dizziness—Dorzolamide—glaucoma	0.000242	0.000775	CcSEcCtD
Levomilnacipran—Rash—Brimonidine—glaucoma	0.000242	0.000774	CcSEcCtD
Levomilnacipran—Dermatitis—Brimonidine—glaucoma	0.000242	0.000773	CcSEcCtD
Levomilnacipran—Dizziness—Travoprost—glaucoma	0.000241	0.000772	CcSEcCtD
Levomilnacipran—Malnutrition—Timolol—glaucoma	0.000241	0.000771	CcSEcCtD
Levomilnacipran—Headache—Brimonidine—glaucoma	0.000241	0.000769	CcSEcCtD
Levomilnacipran—Decreased appetite—Clonidine—glaucoma	0.000241	0.000769	CcSEcCtD
Levomilnacipran—Infection—Betaxolol—glaucoma	0.000239	0.000765	CcSEcCtD
Levomilnacipran—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000239	0.00518	CbGpPWpGaD
Levomilnacipran—Gastrointestinal disorder—Clonidine—glaucoma	0.000239	0.000763	CcSEcCtD
Levomilnacipran—Fatigue—Clonidine—glaucoma	0.000239	0.000762	CcSEcCtD
Levomilnacipran—Dizziness—Brinzolamide—glaucoma	0.000238	0.000762	CcSEcCtD
Levomilnacipran—Nausea—Acetazolamide—glaucoma	0.000238	0.000759	CcSEcCtD
Levomilnacipran—Diarrhoea—Pilocarpine—glaucoma	0.000237	0.000758	CcSEcCtD
Levomilnacipran—Shock—Betaxolol—glaucoma	0.000237	0.000757	CcSEcCtD
Levomilnacipran—Tension—Timolol—glaucoma	0.000237	0.000756	CcSEcCtD
Levomilnacipran—Constipation—Clonidine—glaucoma	0.000237	0.000756	CcSEcCtD
Levomilnacipran—Nervous system disorder—Betaxolol—glaucoma	0.000236	0.000755	CcSEcCtD
Levomilnacipran—Dysgeusia—Timolol—glaucoma	0.000236	0.000755	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Betaxolol—glaucoma	0.000236	0.000754	CcSEcCtD
Levomilnacipran—Tachycardia—Betaxolol—glaucoma	0.000235	0.000751	CcSEcCtD
Levomilnacipran—Skin disorder—Betaxolol—glaucoma	0.000234	0.000748	CcSEcCtD
Levomilnacipran—Vomiting—Dorzolamide—glaucoma	0.000233	0.000745	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Betaxolol—glaucoma	0.000233	0.000744	CcSEcCtD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000232	0.00503	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000231	0.00501	CbGpPWpGaD
Levomilnacipran—Rash—Dorzolamide—glaucoma	0.000231	0.000739	CcSEcCtD
Levomilnacipran—Dermatitis—Dorzolamide—glaucoma	0.000231	0.000738	CcSEcCtD
Levomilnacipran—Rash—Travoprost—glaucoma	0.00023	0.000736	CcSEcCtD
Levomilnacipran—Dermatitis—Travoprost—glaucoma	0.00023	0.000735	CcSEcCtD
Levomilnacipran—Headache—Dorzolamide—glaucoma	0.00023	0.000734	CcSEcCtD
Levomilnacipran—Anorexia—Betaxolol—glaucoma	0.00023	0.000734	CcSEcCtD
Levomilnacipran—Vomiting—Brinzolamide—glaucoma	0.000229	0.000732	CcSEcCtD
Levomilnacipran—Dizziness—Pilocarpine—glaucoma	0.000229	0.000732	CcSEcCtD
Levomilnacipran—Headache—Travoprost—glaucoma	0.000229	0.000731	CcSEcCtD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—EDN1—glaucoma	0.000229	0.00495	CbGpPWpGaD
Levomilnacipran—Nausea—Brimonidine—glaucoma	0.000228	0.000729	CcSEcCtD
Levomilnacipran—Rash—Brinzolamide—glaucoma	0.000227	0.000726	CcSEcCtD
Levomilnacipran—Vision blurred—Timolol—glaucoma	0.000227	0.000726	CcSEcCtD
Levomilnacipran—Dermatitis—Brinzolamide—glaucoma	0.000227	0.000726	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Clonidine—glaucoma	0.000226	0.000723	CcSEcCtD
Levomilnacipran—Headache—Brinzolamide—glaucoma	0.000226	0.000722	CcSEcCtD
Levomilnacipran—Hypotension—Betaxolol—glaucoma	0.000225	0.000719	CcSEcCtD
Levomilnacipran—SLC6A4—Monoamine Transport—TNF—glaucoma	0.000223	0.00482	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000223	0.00482	CbGpPWpGaD
Levomilnacipran—Vomiting—Pilocarpine—glaucoma	0.00022	0.000704	CcSEcCtD
Levomilnacipran—Urticaria—Clonidine—glaucoma	0.00022	0.000702	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFB2—glaucoma	0.00022	0.00476	CbGpPWpGaD
Levomilnacipran—Abdominal pain—Clonidine—glaucoma	0.000219	0.000699	CcSEcCtD
Levomilnacipran—Body temperature increased—Clonidine—glaucoma	0.000219	0.000699	CcSEcCtD
Levomilnacipran—Rash—Pilocarpine—glaucoma	0.000218	0.000698	CcSEcCtD
Levomilnacipran—Dermatitis—Pilocarpine—glaucoma	0.000218	0.000697	CcSEcCtD
Levomilnacipran—Insomnia—Betaxolol—glaucoma	0.000218	0.000696	CcSEcCtD
Levomilnacipran—Nausea—Dorzolamide—glaucoma	0.000218	0.000696	CcSEcCtD
Levomilnacipran—Headache—Pilocarpine—glaucoma	0.000217	0.000694	CcSEcCtD
Levomilnacipran—Nausea—Travoprost—glaucoma	0.000217	0.000693	CcSEcCtD
Levomilnacipran—Paraesthesia—Betaxolol—glaucoma	0.000216	0.000691	CcSEcCtD
Levomilnacipran—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000216	0.00468	CbGpPWpGaD
Levomilnacipran—Syncope—Timolol—glaucoma	0.000216	0.000691	CcSEcCtD
Levomilnacipran—Dyspnoea—Betaxolol—glaucoma	0.000215	0.000686	CcSEcCtD
Levomilnacipran—Nausea—Brinzolamide—glaucoma	0.000214	0.000684	CcSEcCtD
Levomilnacipran—Palpitations—Timolol—glaucoma	0.000213	0.000681	CcSEcCtD
Levomilnacipran—Dyspepsia—Betaxolol—glaucoma	0.000212	0.000678	CcSEcCtD
Levomilnacipran—Loss of consciousness—Timolol—glaucoma	0.000212	0.000677	CcSEcCtD
Levomilnacipran—Decreased appetite—Betaxolol—glaucoma	0.000209	0.000669	CcSEcCtD
Levomilnacipran—Hypertension—Timolol—glaucoma	0.000208	0.000665	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Betaxolol—glaucoma	0.000208	0.000665	CcSEcCtD
Levomilnacipran—Fatigue—Betaxolol—glaucoma	0.000208	0.000664	CcSEcCtD
Levomilnacipran—Constipation—Betaxolol—glaucoma	0.000206	0.000658	CcSEcCtD
Levomilnacipran—Nausea—Pilocarpine—glaucoma	0.000206	0.000658	CcSEcCtD
Levomilnacipran—Chest pain—Timolol—glaucoma	0.000205	0.000656	CcSEcCtD
Levomilnacipran—Anxiety—Timolol—glaucoma	0.000205	0.000654	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000204	0.000651	CcSEcCtD
Levomilnacipran—Hypersensitivity—Clonidine—glaucoma	0.000204	0.000651	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—APOE—glaucoma	0.000202	0.00438	CbGpPWpGaD
Levomilnacipran—Dry mouth—Timolol—glaucoma	0.000201	0.000642	CcSEcCtD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000199	0.0043	CbGpPWpGaD
Levomilnacipran—Asthenia—Clonidine—glaucoma	0.000199	0.000634	CcSEcCtD
Levomilnacipran—Pruritus—Clonidine—glaucoma	0.000196	0.000626	CcSEcCtD
Levomilnacipran—Infection—Timolol—glaucoma	0.000196	0.000625	CcSEcCtD
Levomilnacipran—Shock—Timolol—glaucoma	0.000194	0.000619	CcSEcCtD
Levomilnacipran—Nervous system disorder—Timolol—glaucoma	0.000193	0.000617	CcSEcCtD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000192	0.00417	CbGpPWpGaD
Levomilnacipran—SLC6A2—Monoamine Transport—TNF—glaucoma	0.000191	0.00415	CbGpPWpGaD
Levomilnacipran—Urticaria—Betaxolol—glaucoma	0.000191	0.000612	CcSEcCtD
Levomilnacipran—Skin disorder—Timolol—glaucoma	0.000191	0.000611	CcSEcCtD
Levomilnacipran—Body temperature increased—Betaxolol—glaucoma	0.00019	0.000609	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Timolol—glaucoma	0.00019	0.000608	CcSEcCtD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.00019	0.00411	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Clonidine—glaucoma	0.000189	0.000605	CcSEcCtD
Levomilnacipran—Anorexia—Timolol—glaucoma	0.000188	0.000599	CcSEcCtD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—APOE—glaucoma	0.000186	0.00402	CbGpPWpGaD
Levomilnacipran—Hypotension—Timolol—glaucoma	0.000184	0.000588	CcSEcCtD
Levomilnacipran—Dizziness—Clonidine—glaucoma	0.000183	0.000585	CcSEcCtD
Levomilnacipran—Insomnia—Timolol—glaucoma	0.000178	0.000569	CcSEcCtD
Levomilnacipran—Hypersensitivity—Betaxolol—glaucoma	0.000177	0.000567	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000177	0.00383	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Timolol—glaucoma	0.000177	0.000565	CcSEcCtD
Levomilnacipran—Vomiting—Clonidine—glaucoma	0.000176	0.000562	CcSEcCtD
Levomilnacipran—Dyspnoea—Timolol—glaucoma	0.000175	0.000561	CcSEcCtD
Levomilnacipran—Somnolence—Timolol—glaucoma	0.000175	0.000559	CcSEcCtD
Levomilnacipran—Rash—Clonidine—glaucoma	0.000174	0.000558	CcSEcCtD
Levomilnacipran—Dermatitis—Clonidine—glaucoma	0.000174	0.000557	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—GSTM1—glaucoma	0.000174	0.00376	CbGpPWpGaD
Levomilnacipran—Headache—Clonidine—glaucoma	0.000173	0.000554	CcSEcCtD
Levomilnacipran—Dyspepsia—Timolol—glaucoma	0.000173	0.000554	CcSEcCtD
Levomilnacipran—Asthenia—Betaxolol—glaucoma	0.000173	0.000552	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000173	0.00374	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000172	0.00372	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Timolol—glaucoma	0.000171	0.000547	CcSEcCtD
Levomilnacipran—Pruritus—Betaxolol—glaucoma	0.00017	0.000545	CcSEcCtD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.00017	0.00368	CbGpPWpGaD
Levomilnacipran—Gastrointestinal disorder—Timolol—glaucoma	0.00017	0.000543	CcSEcCtD
Levomilnacipran—Fatigue—Timolol—glaucoma	0.00017	0.000542	CcSEcCtD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000169	0.00367	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000166	0.00359	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Betaxolol—glaucoma	0.000165	0.000527	CcSEcCtD
Levomilnacipran—Nausea—Clonidine—glaucoma	0.000164	0.000525	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000163	0.00352	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—NGFR—glaucoma	0.000162	0.00351	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Timolol—glaucoma	0.000161	0.000514	CcSEcCtD
Levomilnacipran—Dizziness—Betaxolol—glaucoma	0.000159	0.000509	CcSEcCtD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000158	0.00342	CbGpPWpGaD
Levomilnacipran—Urticaria—Timolol—glaucoma	0.000156	0.0005	CcSEcCtD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000156	0.00338	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000156	0.00337	CbGpPWpGaD
Levomilnacipran—Body temperature increased—Timolol—glaucoma	0.000156	0.000497	CcSEcCtD
Levomilnacipran—Abdominal pain—Timolol—glaucoma	0.000156	0.000497	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—NTRK1—glaucoma	0.000154	0.00333	CbGpPWpGaD
Levomilnacipran—Vomiting—Betaxolol—glaucoma	0.000153	0.000489	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—NGF—glaucoma	0.000153	0.00332	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000152	0.0033	CbGpPWpGaD
Levomilnacipran—Rash—Betaxolol—glaucoma	0.000152	0.000485	CcSEcCtD
Levomilnacipran—Dermatitis—Betaxolol—glaucoma	0.000152	0.000485	CcSEcCtD
Levomilnacipran—Headache—Betaxolol—glaucoma	0.000151	0.000482	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—GSTM1—glaucoma	0.000149	0.00323	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Timolol—glaucoma	0.000145	0.000463	CcSEcCtD
Levomilnacipran—Nausea—Betaxolol—glaucoma	0.000143	0.000457	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—CA1—glaucoma	0.000143	0.00309	CbGpPWpGaD
Levomilnacipran—Asthenia—Timolol—glaucoma	0.000141	0.000451	CcSEcCtD
Levomilnacipran—Pruritus—Timolol—glaucoma	0.000139	0.000445	CcSEcCtD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000139	0.00301	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CTSA—glaucoma	0.000138	0.00299	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Timolol—glaucoma	0.000135	0.00043	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—CA2—glaucoma	0.00013	0.00282	CbGpPWpGaD
Levomilnacipran—Dizziness—Timolol—glaucoma	0.00013	0.000416	CcSEcCtD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000128	0.00277	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000128	0.00277	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000127	0.00276	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000127	0.00276	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.000126	0.00272	CbGpPWpGaD
Levomilnacipran—Vomiting—Timolol—glaucoma	0.000125	0.0004	CcSEcCtD
Levomilnacipran—Rash—Timolol—glaucoma	0.000124	0.000397	CcSEcCtD
Levomilnacipran—Dermatitis—Timolol—glaucoma	0.000124	0.000396	CcSEcCtD
Levomilnacipran—Headache—Timolol—glaucoma	0.000123	0.000394	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—FAS—glaucoma	0.000121	0.00261	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000118	0.00255	CbGpPWpGaD
Levomilnacipran—Nausea—Timolol—glaucoma	0.000117	0.000374	CcSEcCtD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000115	0.0025	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL1A—glaucoma	0.000108	0.00234	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTT1—glaucoma	0.000104	0.00225	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000103	0.00224	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000102	0.00221	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—PTGS2—glaucoma	0.0001	0.00217	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—FAS—glaucoma	9.64e-05	0.00209	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—C3—glaucoma	9.5e-05	0.00206	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTT1—glaucoma	9.28e-05	0.00201	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TXN—glaucoma	9.19e-05	0.00199	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—PTGS2—glaucoma	8.95e-05	0.00194	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	8.63e-05	0.00187	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTT1—glaucoma	8.54e-05	0.00185	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	8.41e-05	0.00182	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—APOE—glaucoma	8.38e-05	0.00181	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	8.37e-05	0.00181	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	8.31e-05	0.0018	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP1B1—glaucoma	8.28e-05	0.00179	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP1B1—glaucoma	8.17e-05	0.00177	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	8.14e-05	0.00176	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	7.79e-05	0.00169	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CTSA—glaucoma	7.74e-05	0.00168	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP1B1—glaucoma	7.4e-05	0.0016	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—glaucoma	7.32e-05	0.00158	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP1B1—glaucoma	7.29e-05	0.00158	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CA5A—glaucoma	7.29e-05	0.00158	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NARFL—glaucoma	7.29e-05	0.00158	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTT1—glaucoma	7.12e-05	0.00154	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CTSA—glaucoma	6.91e-05	0.0015	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP1B1—glaucoma	6.8e-05	0.00147	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP1B1—glaucoma	6.71e-05	0.00145	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTM1—glaucoma	6.62e-05	0.00143	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTM1—glaucoma	6.53e-05	0.00141	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NARFL—glaucoma	6.5e-05	0.00141	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA5A—glaucoma	6.5e-05	0.00141	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA5A—glaucoma	6.35e-05	0.00137	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NARFL—glaucoma	6.35e-05	0.00137	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—glaucoma	6.27e-05	0.00136	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	6.07e-05	0.00131	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NARFL—glaucoma	5.98e-05	0.0013	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA5A—glaucoma	5.98e-05	0.0013	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTM1—glaucoma	5.91e-05	0.00128	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTM1—glaucoma	5.83e-05	0.00126	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.74e-05	0.00124	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ABCA1—glaucoma	5.68e-05	0.00123	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1B1—glaucoma	5.68e-05	0.00123	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	5.59e-05	0.00121	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTT1—glaucoma	5.58e-05	0.00121	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	5.56e-05	0.0012	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	5.51e-05	0.00119	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTM1—glaucoma	5.44e-05	0.00118	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	5.36e-05	0.00116	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	5.19e-05	0.00112	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—glaucoma	4.77e-05	0.00103	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	4.76e-05	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTM1—glaucoma	4.54e-05	0.000982	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—glaucoma	4.51e-05	0.000977	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1B1—glaucoma	4.45e-05	0.000963	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	4.39e-05	0.00095	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—glaucoma	4.09e-05	0.000886	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	4.07e-05	0.000881	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MTHFR—glaucoma	4.01e-05	0.000868	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NARFL—glaucoma	3.91e-05	0.000847	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA5A—glaucoma	3.91e-05	0.000847	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	3.8e-05	0.000823	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—APOE—glaucoma	3.73e-05	0.000808	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CAV1—glaucoma	3.7e-05	0.000801	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CA1—glaucoma	3.56e-05	0.000771	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTM1—glaucoma	3.56e-05	0.00077	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	3.51e-05	0.000759	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CTSA—glaucoma	3.45e-05	0.000746	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CA2—glaucoma	3.26e-05	0.000705	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	3.18e-05	0.000689	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	3.18e-05	0.000689	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA1—glaucoma	3.18e-05	0.000688	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA1—glaucoma	3.1e-05	0.000671	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CTSA—glaucoma	3.08e-05	0.000666	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CTSA—glaucoma	3e-05	0.00065	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	2.99e-05	0.000648	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA1—glaucoma	2.92e-05	0.000633	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA2—glaucoma	2.91e-05	0.000629	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	2.84e-05	0.000615	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	2.84e-05	0.000615	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA2—glaucoma	2.84e-05	0.000614	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	2.83e-05	0.000613	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CTSA—glaucoma	2.83e-05	0.000613	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NOS3—glaucoma	2.8e-05	0.000606	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA2—glaucoma	2.67e-05	0.000579	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS2—glaucoma	2.56e-05	0.000554	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	2.36e-05	0.00051	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TXN—glaucoma	2.29e-05	0.000497	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.09e-05	0.000453	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.07e-05	0.000449	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TXN—glaucoma	2.05e-05	0.000443	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	2.02e-05	0.000437	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TXN—glaucoma	2e-05	0.000433	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA1—glaucoma	1.91e-05	0.000414	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TXN—glaucoma	1.88e-05	0.000408	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.87e-05	0.000404	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.85e-05	0.000401	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CTSA—glaucoma	1.85e-05	0.000401	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.78e-05	0.000385	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTT1—glaucoma	1.78e-05	0.000385	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA2—glaucoma	1.75e-05	0.000378	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—glaucoma	1.59e-05	0.000344	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—glaucoma	1.55e-05	0.000335	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—glaucoma	1.46e-05	0.000316	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.43e-05	0.00031	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCA1—glaucoma	1.42e-05	0.000307	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1B1—glaucoma	1.42e-05	0.000307	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.28e-05	0.000277	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCA1—glaucoma	1.26e-05	0.000274	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1B1—glaucoma	1.26e-05	0.000274	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1B1—glaucoma	1.23e-05	0.000267	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ABCA1—glaucoma	1.23e-05	0.000267	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TXN—glaucoma	1.23e-05	0.000267	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCA1—glaucoma	1.16e-05	0.000252	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1B1—glaucoma	1.16e-05	0.000252	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—glaucoma	1.13e-05	0.000245	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—glaucoma	1.01e-05	0.000219	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—glaucoma	1e-05	0.000217	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—glaucoma	9.87e-06	0.000214	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—glaucoma	9.54e-06	0.000207	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOE—glaucoma	9.32e-06	0.000202	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—glaucoma	9.3e-06	0.000201	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CAV1—glaucoma	9.23e-06	0.0002	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—glaucoma	8.94e-06	0.000193	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—glaucoma	8.72e-06	0.000189	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOE—glaucoma	8.32e-06	0.00018	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CAV1—glaucoma	8.24e-06	0.000178	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—glaucoma	8.22e-06	0.000178	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOE—glaucoma	8.12e-06	0.000176	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CAV1—glaucoma	8.04e-06	0.000174	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOE—glaucoma	7.65e-06	0.000166	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCA1—glaucoma	7.6e-06	0.000165	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1B1—glaucoma	7.6e-06	0.000165	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CAV1—glaucoma	7.58e-06	0.000164	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NOS3—glaucoma	6.98e-06	0.000151	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—glaucoma	6.39e-06	0.000138	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NOS3—glaucoma	6.23e-06	0.000135	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NOS3—glaucoma	6.08e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—glaucoma	6.08e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NOS3—glaucoma	5.73e-06	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—glaucoma	5.7e-06	0.000123	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—glaucoma	5.56e-06	0.00012	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—glaucoma	5.37e-06	0.000116	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—glaucoma	5.24e-06	0.000114	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOE—glaucoma	5e-06	0.000108	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CAV1—glaucoma	4.96e-06	0.000107	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NOS3—glaucoma	3.75e-06	8.11e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—glaucoma	3.43e-06	7.42e-05	CbGpPWpGaD
